Search - tctmd.com

Displaying 361 - 380 of 408

Sort: Relevancy | Date

News Daily News

Refreshed Dietary Guidelines Shift Focus to Healthy Eating Patterns

January 18, 2016

News Daily News

Sweet Surrender? Trimming Sweetness from Sugary Drinks May Cut Obesity-Related Diseases

January 06, 2016

News Daily News

AHA Scientific Statement Highlights Sex Disparities in CV Risk Among Diabetic Patients

December 09, 2015

News Daily News

Sugary Drinks an Increasing Threat to Global Cardiometabolic Health

December 02, 2015

News Industry News

Jardiance® (empagliflozin) is the only diabetes medication to show a significant reduction in both cardiovascular risk and cardiovascular death in a dedicated outcome trial

September 18, 2015

News Conference News ESC 2015

ESC Congress 2015: Presentations Sift Clinical Wheat From Chaff

September 09, 2015

News Conference News ESC 2015

Ezetimibe Benefits Diabetics, and Does Not Increase Risk of New-Onset Diabetes

Yael L. Maxwell

September 01, 2015

News Conference News ESC 2015

TECOS: No Differences in Heart Failure Outcomes When Sitagliptin Added to Usual Care in Diabetics

Yael L. Maxwell

August 31, 2015

News Conference News ESC 2015

Novel Diabetes Drug Shows No Sign of Increasing Events in ACS Patients

August 31, 2015

News Conference News ESC 2015

FREEDOM Substudy: CABG, PCI Outcomes Affected by Baseline BP

Yael L. Maxwell

August 30, 2015

News Daily News

Registry Study Suggests Absorb BVS Matches DES in Diabetic All-Comers

August 27, 2015

News Industry News

Jardiance® demonstrated cardiovascular (CV) risk reduction in people with type 2 diabetes at high risk for CV events

August 20, 2015

News Daily News

High Troponin T Foretells Poor Outcomes in Patients With Type 2 Diabetes, Stable Heart Disease

August 17, 2015

News Daily News

Novel Antisense Inhibitor Cuts High Triglyceride Levels

August 13, 2015

News Daily News

BARI 2D: Increased Risk Factor Control in Patients With Type 2 Diabetes Ups Survival

Yael L. Maxwell

August 12, 2015

News Industry News

Resverlogix Officially Attains Phase 3 Status with a European Regulatory Authority

June 22, 2015

News Industry News

First CVD Outcome Trial of a GLP-1 Agonist Finds No Cardiac Risk or Benefit

June 09, 2015

News Industry News

Takeda Presents Additional Data from Alogliptin's EXAMINE Cardiovascular Safety Outcomes Trial at the American Diabetes Association's 75th Scientific Sessions

June 05, 2015

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.